Neuburgh Advisers’s Novo Nordisk NVO Stock Holding History

Neuburgh Advisers’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-16,448	Closed	-$388K	–	919
2018 Q3	$388K	Hold	16,448	–	–	0.01%	542
2018 Q2	$379K	Hold	16,448	–	–	0.01%	492
2018 Q1	$405K	Hold	16,448	–	–	0.01%	464
2017 Q4	$441K	Hold	16,448	–	–	0.02%	464
2017 Q3	$396K	Hold	16,448	–	–	0.01%	444
2017 Q2	$353K	Hold	16,448	–	–	0.01%	455
2017 Q1	$282K	Hold	16,448	–	–	0.01%	443
2016 Q4	$295K	Buy	+16,448	New	+$298K	0.01%	408

Other funds holding NVO

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

State Farm Mutual Automobile Insurance Bloomington, Illinois $127B AUM 32.55% 1-Year Est. Return

Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return

Neuburgh Advisers's NVO Position: Q4 2018 in Review

Neuburgh Advisers sold out of Novo Nordisk (NVO) in Q4 2018, closing a stake of 16,448 shares — an estimated $388K sold.

Neuburgh Advisers first reported a position in NVO in Q4 2016 and held it in 8 quarters. The position peaked at $441K in Q4 2017. 550 funds tracked by Wall St. Rank hold NVO as of Q4 2018.

Neuburgh Advisers reported no remaining Novo Nordisk position as of Q4 2018 after selling out during the quarter.
Neuburgh Advisers sold 16,448 Novo Nordisk shares in Q4 2018, an estimated $388K.
Neuburgh Advisers first reported a position in Novo Nordisk in Q4 2016 and held it in 8 quarters.
Neuburgh Advisers's Novo Nordisk position peaked at $441K in Q4 2017.
550 funds tracked by Wall St. Rank held Novo Nordisk as of Q4 2018.

Based on Neuburgh Advisers's 13F filing for Q4 2018, filed 13 Feb 2019.